In a study, cardiologists and the decision support system, called ARTificial Intelligence for clinical Cardiac nAvigation, or ARTICA, both examined 982 patients with stable chest pain. While the physicians determined that less than 5 percent of the patients could refrain from further testing, ARTICA advised no further testing for 67 percent.
After CT angiography scans were conducted on all the patients, 97 percent of those ARTICA said required no further testing were found to have no significant coronary artery disease, thus proving the AI correct. On average, ARTICA’s recommendations could save healthcare providers one hour and patients two hours, plus the costs of pricey CTA scans.
However, ARTICA is less accurate when determining which patients do require further testing. “We know that when ARTICA says don’t do a test it is almost 100 percent right,” Marco Mazzanti, MD, study author and cardiologist at London’s Royal Brompton Hospital, said in a statement. “When ARTICA decides a test is needed, we are less certain that this is correct. By adding more data to the ‘super brain’ these decisions will become more accurate and enable us to deliver more personalized care.”
More articles about AI:
AI retinal scanner that can detect Alzheimer’s given FDA ‘Breakthrough Device’ status
Harvard Business Review: Look at AI as a system-wide update, not a point solution
Catasys will use AI, human interaction to address loneliness epidemic
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
